AF has blocked me from following his tweets because on rare occasion I have bothered to respond with negative comments re NWBO. He can dish out his twisted, highly biased agenda on NWBO, but he cannot take any negative comment. I am not sure how he can look in the mirror in the morning.
I am not the only one AF has blocked. He has built up a large negative following some of whom do not hestiate to comment.
Form 8-K for NORTHWEST BIOTHERAPEUTICS INC
Regulation FD Disclosure, Financial Statements and Exhibits
Item 7.01. Regulation FD Disclosure.
In response to a question received from a stockholder of Northwest Biotherapeutics, Inc. (the "Company") relating to the Company's recently issued proxy statement and asking whether Toucan Partners, LLC sold 2,099,400 shares in 2014, the Company provided the response set forth in Exhibit 99.1 hereto. The information in this Item 7.01, including the exhibit attached hereto, is furnished solely pursuant to Item 7.01 of Form 8-K. Consequently, such information is not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Further, the information in this Item 7.01, including the exhibit, shall not be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933.
For the opportunity to buy more NWBO more cheaply than I expected. I just tanked up big time this morning. I look forward to seeing much more of your market moving but uninformed drivel so that I can still get more NWBO before it eventually takes off. Keep up the good work (for me that is).
I would imagine this should be important if investors see a much shorter time to probable payoff!
I believe that all the recent great news for DC-VAX will give enrollment in the trials a large boost, as more people with these cancers (both glio and other solid tumors) will be demanding entry into these trials, so I think we can assume that the close of the trials will be much earlier than previously projected if in fact not given AA much sooner in any case. I think we are in for a very good week ahead, but if the market is slow to respond to all this good news I will be scooping up more NWBO shares to the extent my available funds permit. Whether I bought at $4.20 or $6.50 will be a minor issue when I look back from a $100 share price. This is the time to get in on the next GSK, MERK, MSFT, INTL or GOOG (or bigger) in the making.
GOOD! Money does not grow on trees. They need the money to to the trials on these wonderful cancer treatments. so yea , you are right but that is how things get done and this will make us investors rich.
I wonder if the authors of the poster most of whom are with MDAnderson are barred from trading NWBO stock as "insiders" before publication of the poster at SITC? If not, (and the news is good) they should be placing large bets!
If the data has improved over the last three months since the abstract was written then they would not want to release the abstract early but would wait for the oral presentation when they they can inform us that the data has further improved since the abstract was written.
Usually there is a drop off to the end of the day as the day traders exit. Not today. I think some of the shorts are starting to see the writing on the wall and are trying to cover before the end of the day in case the release of the abstract tomorrow is a trigger for much higher prices as many are predicting. Slow today but with a nice increase so far, but if the abstract has some powerful news in the morning then whatch as a major short squeese unfolds tomorrow and hello double digit share prices.
About a year ago or so when AEGR was selling near its peak at almost $100 US, I suggested you sell some AEGR and buy PLI with that money. At that time it was about 75 cents Canadian. That is approx a ratio of 133 to 1 as it looked like PLI wold develop more prphan drugs than the only one AEGR had going for it with a highly inflated stock price - so tuned that if anything went wrong the SP would plummet - which is exactly what happened. In the meantime PLI continued on its meteoric rise which is only just getting started. It is at $1.64 C$ today and just starting its climb while AEGR has now fallen to about $20. That is now a ratio of aprox 12 to 1 - quite some change! Well the good news is that it isnot too late to buy PLI it climb is just starting!
Glta with another stock.
You mean zero selling pressure! All the shorts are trying to cover lower but no oone selling!
This "analysis" done by TheStreet isn't worth the (electronic) paper it's printed on! It is preprogrammed and nearly mindless and worthless IMO. Not worth reading in my opinion.
It's not the percentage of downside risk that matters so much as the absolute number of dollars at risk, For LP this number is huge, by any account (even with discounted shares) she has a huge number of dollars at risk - easily in the many tens of millions of dollars.
Actually I tried to do that but the sign in program wouldn't let me in. If you don't mind could you post this for me at the AtTheStreet comments noting my post on Yahoo. Thanx
You ask: "Why would hedge funds be motivated to short shares of Northwest Biotherapeutics and put the company out of business?"
The answer is very simple:because NWBO is a small biotech with no income and needs funding which in today's environment is not easy to obtain. So they are easy prey at the mercy of Hedge Funds with deep pockets. This is a sure thing (while no news is out or like today when the entire market is down big time) for them (short term) while going long is not a sure thing and requires a long term commitment.
You write: "They overlook the details showing most of Powers' holdings come from preferentially priced warrants and stock payments tied to her ownership of Cognate BioServices."
The obvious response is simple: Sure, it is debatable whether LP received "preferentially priced warrants and stock," but the point is they were still far from free and it is clear she wants a significant holding in NWBO because she strongly believes NWBO will succeed and she is not the pied piper leading the poor blind investors to their doom as you seem to imply.
You further write: "if DCVax-L blows up, Northwest's stock will fall even further and shareholder equity will be decimated. Cognate and Powers do not shoulder the same level of financial risk. If the ongoing DCVax-L phase III brain cancer study is shut down or fails, Cognate and Powers have a $3 million or $5 million cash safety net to cushion the blow. For Powers, negotiating with herself has its privileges."
Again the response is quite obvious and simple: You ignore the size of her holding. Sure, she will be cushioned to the extent of $3 or $5 million, but that will be very small comfort to her huge loss of about $100,000,000 million dollars. so I would say her interests are still very much aligned with the investor (being the largest share holder).
You complain: "Northwest Bio priced the $15 million April equity raise at $6.60 per share, so Tuesday's deal was done at a 31% discount to that last equity raise."
Again the response is obvious, that is the current market price and 3rd party has no interest in negotiating a higher value than that when dealing with a co who needs the money and has the upper hand in the negotiations.
Finally, why Adam do you almost never make a direct frontal attack on the merits of the science involved. Your attacks are on ethics, procedure, lack of released info implying impropriety, preferential share price for LP. You twist the words of the company to suit your agenda but never get to the key point - the merits of the science. These are the fundamentals the will govern the success of the trials and of this investment - not whether LP is getting a better deal (who is taking on tremendous risk) than the rest of us. What on Earth makes you so sure that the trials will fail in the face of all the good news so far. Even you can not call the news release so far as bad news. You make the assertion in your rule that small caps fail - clearly even if that is true more often than not, there are certainly many exceptions to that rule - this is one of them. Furthermore, if you look at trials in general you will find that large cap trials often fail as well so even the bald assertion does not make sense or you would bet against all biotech companies doing trials. So that rule really gets you nowhere - it is a mere slogan for your assertion of failure when it suits your agenda.